Difference between revisions of "Vincristine (Oncovin)"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
*[[Acute lymphocytic leukemia]] | *[[Acute lymphocytic leukemia]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
| + | *[[Burkitt lymphoma]] | ||
*[[Central nervous system (CNS) cancer]] | *[[Central nervous system (CNS) cancer]] | ||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| Line 27: | Line 29: | ||
*[[Sarcoma]] | *[[Sarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| − | |||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
| + | </div> | ||
==Notable side effects== | ==Notable side effects== | ||
| Line 134: | Line 136: | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
| + | [[Category:Burkitt lymphoma medications]] | ||
[[Category:Central nervous system (CNS) cancer medications]] | [[Category:Central nervous system (CNS) cancer medications]] | ||
[[Category:Central nervous system (CNS) lymphoma medications]] | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
| Line 151: | Line 154: | ||
[[Category:Sarcoma medications]] | [[Category:Sarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| − | |||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Drugs FDA approved in 1963]] | [[Category:Drugs FDA approved in 1963]] | ||
Revision as of 00:59, 13 May 2015
General information
Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Anaplastic large cell lymphoma
- Bone cancer
- Burkitt lymphoma
- Central nervous system (CNS) cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- CNS lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Follicular lymphoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Neuroendocrine tumors
- Penile cancer
- Peripheral T-cell lymphoma
- Sarcoma
- Small cell lung cancer
- Thymoma
- Transplant conditioning regimens
Notable side effects
- Neuropathy [3]
Patient drug information
- Vincristine (Oncovin) patient drug information (Chemocare)[4]
- Vincristine (Oncovin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 7/10/1963: Initial FDA approval
Also known as
Precise Name: vinCRIStine Sulfate (RXCUI 11203)
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Alcrist | Biocrist | Biocrystin | Cellcristin | Citomid | Citomid RU | Crivosin | Cytomid |
| Farmistin CS | Fauldvincri | Krebin | Kyocristine | Nevexitin | Oncocristin AQ | Oncovin ELI Lilly | Oncovin INJ.LSG. |
| Oncovin Yamakawa | Onkocristin | P&U Vincristine | Pericristine | Pharmacristine | Tecnocris | Trav Vincristine | Vero Vincristin |
| Vincasar | Vincasar PFS | Vinces | Vincosid | Vincran | Vincrex | Vincrifil | Vincrin |
| Vincrisin | Vincrisol | Vincristin | Vincristina | Vincristina Faulding | Vincristina Filaxis | Vincristina Martian | Vincristin Biosyn |
| Vincristin CS | Vincristine | Vincristine Abic | Vincristine Comp | Vincristine DBL | Vincristine Lederle | Vincristine Mayne | Vincristine Mayne Pharma ( BEN ) |
| Vincristine Pharmachemie | Vincristinesulfaat | Vincristine Sulfate | Vincristine Sulfate Synthelabo | Vincristine Sulp | Vincristine Sulphate | Vincristine Teva | Vincristinsulfat |
| Vincristin Sulfate | Vincristinum | Vincrisul | Vinracin | Vinracine | Vinstin | Vintec | |
References
- ↑ 1.0 1.1 Vincristine (Oncovin) package insert
- ↑ Vincristine (Oncovin) package insert (locally hosted backup)
- ↑ Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010 Nov;11(11):1057-65. Epub 2010 Sep 21. link to original article contains verified protocol PubMed
- ↑ Vincristine (Oncovin) patient drug information (Chemocare)
- ↑ Vincristine (Oncovin) patient drug information (UpToDate)
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Vesicant chemotherapy
- Microtubule inhibitors
- Vinca alkaloids
- Acute lymphocytic leukemia medications
- Aggressive Non-Hodgkin lymphoma medications
- Anaplastic large cell lymphoma medications
- Bone cancer medications
- Burkitt lymphoma medications
- Central nervous system (CNS) cancer medications
- Central nervous system (CNS) lymphoma medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Neuroendocrine tumor medications
- Penile cancer medications
- Peripheral T-cell lymphoma medications
- Sarcoma medications
- Small cell lung cancer medications
- Thymoma medications
- Transplant medications
- Drugs FDA approved in 1963